By Fineline Cube 
Novlead Biotech, a Nanjing-based specialist in nitric oxide (NO) gas detection and treatment, has secured “hundreds of millions” of renminbi in a Series C financing round. Led by D&T Capital, the funding round included contributions from Yangzhou Guojin Investment, Zhongshan Investment Holding, Triwise Capital, Efung Capital, and Xingxiang Investment. The proceeds will be allocated toward expanding manufacturing capacity, commercial promotion, and overseas business development for its portable NO inhalation therapy device, as well as advancing its innovative pipeline centered on NO release and generation technology.
Funding and Strategic Allocation
The funds raised will primarily support the expansion of Novlead’s manufacturing capabilities to meet growing demand for its portable NO inhalation therapy device. Additionally, the company plans to intensify commercialization efforts and explore international markets, leveraging its technological advantages in NO-based therapies. The investment will also fuel the development of next-generation products and innovative pipelines, further solidifying Novlead’s position as a leader in the field.
Product Innovation and Market Adoption
Novlead’s flagship product, the INOwill portable NO inhalation therapy device, is a Category III medical device approved for marketing in China in 2022. Notably, INOwill is designed without a steel cylinder, offering significant advantages in convenience, safety, and effectiveness. Since its launch, the device has been rapidly adopted by hundreds of hospitals both domestically and internationally, finding applications in critical departments such as neonatal ICUs, adult ICUs, and cardiac surgery units.
Company Background and Vision
Founded in 2018, Novlead Biotech has established itself as a pioneer in NO gas detection and therapeutic applications. With a strong focus on innovation and patient-centric solutions, the company continues to push the boundaries of NO technology, aiming to transform treatment paradigms in respiratory and critical care medicine.-Fineline Info & Tech